Artificial Tears Study in Mild to Moderate Dry Eye Patients

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00607776

Enrollment

110

Registered

2008-02-06

Start date

2007-01-31

Completion date

2007-04-30

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye

Keywords

dry, eyes, Amelioration of dry eye symptoms

Brief summary

The mean change in the subjective comfort score from baseline of the test group is at least 2.0 units less than that of the control group.

Interventions

DRUG(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400

Drops

DRUGSystane

Drops

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Mild to moderate dry eye * over 18

Exclusion criteria

* No concurrent ocular disease or meds

Design outcomes

Primary

Measure	Time frame
Subjective ocular comfort	1 Month

Secondary

Measure	Time frame
Vision quality	1 Month

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026